利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

17 条记录 (耗时 0.044 秒)

    Tissue targeted complement modulators
    13.
    发明授权
    Tissue targeted complement modulators 失效
    组织靶向补体调节剂

    公开(公告)号：US08454963B2

    公开(公告)日：2013-06-04

    申请号：US11116939

    申请日：2005-04-28

    申请人： Stephen Tomlinson ,  Richard J. Quigg

    发明人： Stephen Tomlinson ,  Richard J. Quigg

    IPC分类号： A61K38/00 ,  C07K16/28 ,  C07K14/705

    CPC分类号： C07K14/70596 ,  C07K14/705 ,  C07K16/2896 ,  C07K2319/00 ,  C07K2319/30

    摘要： Systemic suppression of the complement system has been shown to be effective to treat inflammatory disease, yet at the potential cost of compromising host defense and immune homeostasis. Herein disclosed are methods for antigen-specific targeting of complement inhibitors that show that complement inhibitors targeted to the proximal tubular epithelium protect against tubulointerstitial injury and renal dysfunction in a rat model of nephrosis. It is shown that appropriate targeting of a systemically administered complement inhibitor to a site of disease markedy enhances efficacy and obviates the need to systemically inhibit complement. Additionally, it is shown by specifically inhibiting the terminal pathway of complement, that the membrane attack complex (MAC) plays a key role in proteinuria-induced tubulointerstitial injury, thus establishing the MAC as a valid target for pharmacological intervention in proteinuric disorders. The disclosed are compositions can be used in methods of treating pathogenic diseases and inflammatory conditions by modulating the complement system.

    摘要翻译： 补体系统的系统抑制已被证明是有效治疗炎性疾病，但是潜在的牺牲宿主防御和免疫稳态的代价。 本文公开的是用于补体抑制剂的抗原特异性靶向的方法，其显示针对近端肾小管上皮的补体抑制剂保护肾小管模型中的肾小管间质损伤和肾功能障碍。 已经表明，将系统给药的补体抑制剂适当靶向标记的疾病部位增强功效，并且避免需要系统地抑制补体。 另外，通过特异性抑制补体的末端途径显示，膜攻击复合物（MAC）在蛋白尿诱导的肾小管间质损伤中起关键作用，从而建立MAC作为蛋白质性疾病药理学干预的有效靶标。 所公开的是组合物可以用于通过调节补体系统来治疗病原性疾病和炎性病症的方法。

    Human CD59 mutants with modulated complement binding activity
    16.
    发明申请
    Human CD59 mutants with modulated complement binding activity 审中-公开
    具有调节的补体结合活性的人CD59突变体

    公开(公告)号：US20100036095A1

    公开(公告)日：2010-02-11

    申请号：US11997650

    申请日：2006-08-01

    申请人： Stephen Tomlinson

    发明人： Stephen Tomlinson

    IPC分类号： C07K14/705

    CPC分类号： C07K14/70596

    摘要： Disclosed are compositions and methods using mutant CD59. Also disclosed is new insight into the CD59-C8/C9 binding interface and engineered soluble CD59 molecules with significantly improved complement inhibitory activity.

    摘要翻译： 公开了使用突变体CD59的组合物和方法。 还公开了对于具有显着改善的补体抑制活性的CD59-C8 / C9结合界面和工程可溶性CD59分子的新见解。

    Tissue targeted complement modulators
    17.
    发明申请
    Tissue targeted complement modulators 失效
    组织靶向补体调节剂

    公开(公告)号：US20050265995A1

    公开(公告)日：2005-12-01

    申请号：US11116939

    申请日：2005-04-28

    申请人： Stephen Tomlinson ,  Richard Quigg

    发明人： Stephen Tomlinson ,  Richard Quigg

    IPC分类号： A61K39/395 ,  C07K14/705 ,  C07K16/28

    CPC分类号： C07K14/70596 ,  C07K14/705 ,  C07K16/2896 ,  C07K2319/00 ,  C07K2319/30

    摘要： Systemic suppression of the complement system has been shown to be effective to treat inflammatory disease, yet at the potential cost of compromising host defense and immune homeostasis. Herein disclosed are methods for antigen-specific targeting of complement inhibitors that show that complement inhibitors targeted to the proximal tubular epithelium protect against tubulointerstitial injury and renal dysfunction in a rat model of nephrosis. It is shown that appropriate targeting of a systemically administered complement inhibitor to a site of disease markedy enhances efficacy and obviates the need to systemically inhibit complement. Additionally, it is shown by specifically inhibiting the terminal pathway of complement, that the membrane attack complex (MAC) plays a key role in proteinuria-induced tubulointerstitial injury, thus establishing the MAC as a valid target for pharmacological intervention in proteinuric disorders. The disclosed are compositions can be used in methods of treating pathogenic diseases and inflammatory conditions by modulating the complement system.

    摘要翻译： 补体系统的系统抑制已被证明是有效治疗炎性疾病，但是潜在的牺牲宿主防御和免疫稳态的代价。 本文公开的是用于补体抑制剂的抗原特异性靶向的方法，其显示针对近端肾小管上皮的补体抑制剂保护肾小管模型中的肾小管间质损伤和肾功能障碍。 已经表明，将系统给药的补体抑制剂适当靶向标记的疾病部位增强功效，并且避免需要系统地抑制补体。 另外，通过特异性抑制补体的末端途径显示，膜攻击复合物（MAC）在蛋白尿诱导的肾小管间质损伤中起关键作用，从而建立MAC作为蛋白质性疾病药理学干预的有效靶标。 所公开的是组合物可以用于通过调节补体系统来治疗病原性疾病和炎性病症的方法。